Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Confirmation of reduction of capital

June 10, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has yesterday

Proposed dual-listing on Nasdaq

May 18, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has confidentially

Result of General Meeting

May 15, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and

Removal of US Securities Law Restrictions on Ordinary Shares

May 5, 2020
Download  full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that, following legal advice, it has taken the decision to remove the offering restrictions imposed by US securities law

Provider network agreement for KidneyIntelX™

April 15, 2020
Download  full announcement Agreement with Three Rivers Provider Network, the fastest growing US proprietary provider network KidneyIntelX   risk assessment testing now available to Three Rivers members and clients Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial
Displaying 131 - 140 of 203